All In Biotech

Drug Trial Radar · NCT03610516

Safety, Pharmacokinetics and Preliminary Efficacy Study of CFZ533 in Patients With Lupus Nephritis.

A Randomized, Placebo-controlled, Patient and Investigator Blinded, Study Investigating the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Multiple Doses of CFZ533 in Patients With Moderately Active Proliferative Lupus Nephritis

Last checked: Nov 19, 2026Latest source record: Oct 9, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

57

Actual

Start

Sep 12, 2018

Primary completion

Jun 29, 2023

Study completion Jun 29, 2023

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Aug 1, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study was to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary therapeutic efficacy of multiple doses of CFZ533 anti-CD40 monoclonal antibody in patients with moderately active lupus nephritis.

Conditions

  • Lupus Nephritis

Interventions

  • CFZ533Drug

    Multiple doses of 10 mg/kg CFZ533 intravenous (IV) infusion. CFZ533 was administered every 4 weeks (Q4W; from Day 1 to Day 141), plus an additional dose of 10 mg/kg IV at Day 15, resulting in a Q2W loading regimen up to the third dose on Day 29.

  • PlaceboDrug

    multiple doses of placebo intravenous infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: Adverse events were reported from first dose of study treatment until end of study treatment plus follow up period, up to a maximum duration of approximately 49 weeks.
  2. Ratio to Baseline in Urinary Protein Creatinine Ratio (UPCR)Time frame: Baseline, Day 169

Locations

21 sites in 10 countries. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Córdoba, Argentina

  • Novartis Investigative Site

    Ciudad Autonoma de Bs As, Buenos Aires, Argentina

  • Novartis Investigative Site

    Beijing, China

  • Novartis Investigative Site

    Shanghai, China

  • Novartis Investigative Site

    Guangzhou, Guangdong, China

  • Novartis Investigative Site

    Changsha, Hunan, China

  • Novartis Investigative Site

    Ürümqi, Xinjiang, China

  • Novartis Investigative Site

    Mainz, Germany

  • Novartis Investigative Site

    Hong Kong, Hong Kong

  • Novartis Investigative Site

    Debrecen, Hungary

  • Novartis Investigative Site

    Rostov-on-Don, Russia

  • Novartis Investigative Site

    Saint Petersburg, Russia

  • Novartis Investigative Site

    Saint Petersburg, Russia

  • Novartis Investigative Site

    Yaroslavl, Russia

  • Novartis Investigative Site

    Seoul, South Korea

  • Novartis Investigative Site

    Seoul, Seocho Gu, South Korea

  • Novartis Investigative Site

    Taichung, Taiwan

  • Novartis Investigative Site

    Taichung, Taiwan

  • Novartis Investigative Site

    Taipei, Taiwan

  • Novartis Investigative Site

    Tunis, Tunisia

  • Novartis Investigative Site

    Kocaeli, Turkey (Türkiye)

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.